Navigation Links
Uroplasty Reports Third Quarter Fiscal 2009 Results
Date:2/3/2009

.

Net loss for the third fiscal quarter ended December 31, 2008 was $894,000, or $0.06 per diluted share versus $900,000, or $0.06 per diluted share for the third quarter of last year. For the nine months ended December 31, 2008, net loss was $1.9 million, or $0.12 per diluted share compared with a net loss of $3.1 million, or $0.23 per diluted share for the same period last year.

At December 31, 2008, cash and cash equivalents, and short-term investments were $8.6 million compared with $9.0 million at September 30, 2008 and $10.1 million at March 31, 2008.

"We continue to implement a comprehensive program designed to educate Medicare carrier and private payer medical directors around the country about the benefits and clinical study results of Urgent PC," continued Mr. Kaysen. "The medical directors have asked for additional peer-reviewed publications in medical journals on PTNS treatments. We expect the first of such articles to be published within the next 30 days."

"In the meantime, physicians using Urgent PC are communicating their successes to these medical directors and we are in active communication with professional associations who are involved with reimbursement and believe we have the right people and the right resources to proactively address various reimbursement related issues. It is important to remember that reimbursement uncertainties are common with practically every new medical technology. Gaining a specific CPT code for the procedure is our end goal and we believe our strategies to achieve that endpoint are generating positive responses from the market and will lead to achieving our objective," Mr. Kaysen concluded.

Guidance

For fiscal 2009, the Company currently expects overall sales to grow by approximately 4% to 7% over fiscal 2008, and U.S. sales to grow between 20% and 25%. The Company continues to expect consistent operating inco
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015 The Pistoia Alliance, ... work together to lower barriers to innovation in R&D, ... project. , The Ontologies Mapping project has been ... practices for ontology management in life sciences R&D. The ... of standardized guidelines, tools and services to enable the ...
(Date:4/28/2015)... According to a 2013 report from ... medical treatment from burn injuries per year. Despite several ... formation of scars with subsequent contractures remains a major ... there is no adequate treatment. Contractures are a permanent ... can cause permanent deformity. , Synedgen has developed ...
(Date:4/28/2015)... 28, 2015 Reproductive endocrinologist Dr. Kaylen ... 7 couples battling infertility in this country, testified on behalf ... as the first state in the nation to consider creating ... to couples who desire to receive them. , Infertility affects ... that infertility is one of the few medical diseases that ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... patente para un nuevo receptor utilizando tecnología de descubrimiento ... no cubierta en el tratamiento de millones de pacientes ... anunciado hoy que ha recibido una patente en Europa ... el descubrimiento de Molecular Health de que EPHB4 es ...
Breaking Biology Technology:Pistoia Alliance Announces Start of Ontologies Mapping Project 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3
... 6 , 3Q09 Corporate Highlights: ... to Astellas Pharma Europe Ltd. Made significant progress ... VP Sales; Senior Director, Marketing; and Director, Commercial Operations ... Committee chairman , Upcoming 2009 Milestones: ...
... Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced ... REOLYSIN(R) in patients with sarcomas metastatic to the lung ... Tissue Oncology Society Meeting held in Miami Beach, Florida, ... "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) ...
... ... place on February 22-24, 2010 in Philadelphia, has been announced. At this three day ... to share their experiences. , ... Minneapolis, MN (PRWEB) November 6, 2009 -- The agenda for Arrowhead’s ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... decades, crop breeders have increasingly relied on the wild and ... resistance, drought tolerance, and other traits. But just like all ... at risk of decline and extinction due to habitat loss, ... two speakers will describe the latest efforts to identify and ...
... Ohio The discovery of genetic differences affecting up ... guesswork out of prescribing the correct dose of 25 ... The scientists found two genetic variants that alter ... or metabolizing, drugs ranging from the painkiller codeine to ...
... 10 per cent of the UK is left handed ... world. But why exactly someone is left or right handed ... Nottingham,s Professor John Armour and Dr Angus Davison, in collaboration ... genetic determinant, in influencing handedness. The researchers conducted ...
Cached Biology News:Protecting the weedy and wild kin of globally important crops 2New genetic discovery could reduce the guesswork in drug dosing 2New genetic discovery could reduce the guesswork in drug dosing 3New genetic discovery could reduce the guesswork in drug dosing 4What makes us left or right handed? New study rules out strong genetic factors 2